These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9123706)

  • 1. Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy.
    Pruthi RS; Haese A; Huland E; Stamey TA
    Urology; 1997 Mar; 49(3):404-10. PubMed ID: 9123706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR; Lapeyrolerie T
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The periurethral glands do not significantly influence the serum prostate specific antigen concentration.
    Oesterling JE; Tekchandani AH; Martin SK; Bergstralh EJ; Reichstein E; Diamandis EP; Yemoto C; Stamey TA
    J Urol; 1996 May; 155(5):1658-60. PubMed ID: 8627847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S; Lepor H; Yaffee R; Taneja SS
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
    Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
    Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
    Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC
    J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay.
    Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK
    Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
    Vaidya A; Soloway MS
    J Urol; 2000 Dec; 164(6):1998-2001. PubMed ID: 11061900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.